An interventional study of Clinical examination centered on congestion and Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography in Chronic Heart Failure and Preserved Ejection Fraction, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-05.
Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Heart Failure by Central Hospital, Nancy, France — 9 open to participants now, 10 under way, 1 of them phase 3. Heart Failure · Central Hospital, Nancy, France.
Among the 19 studies in Heart Failure by Central Hospital, Nancy, France, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2022, is one of 12 with no phase, and was the 12th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →9 of the 19 studies in Heart Failure by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 103 across the 13 interventional studies, 207 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
3 of the studies in Heart Failure by Central Hospital, Nancy, France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
| NCT06868797Central Hospital, Nancy, FranceAcute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List | 2027-02-28 |
| NCT07468344Central Hospital, Nancy, FranceEvaluation of the Effects of Sauna Therapy on Congestion and Loop Diuretic Use in Patients With Heart Failure With Reduced or Moderately Reduced Ejection Fraction | 2027-09-23 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Heart Failure by Central Hospital, Nancy, France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation.
The main objective of the CHF-COV Preserved study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF with preserved left ventricular ejection fraction that are associated with the risk of all-cause death, hospitalization for acute HF or IV diuretics injection in a day hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Clinical examination focusing on congestion * Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds * Blood sample retrieved for biological assessment and biobanking * Telephone follow-up
Procedure: Clinical examination centered on congestion · Procedure: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography · Procedure: Blood and urine sample retrieved for biological assessment and biobanking · Other: Telephone follow-up · Behavioral: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Clinical examination centered on congestion (including the EVEREST, Ambrosy and ASCEND score) will be performed during day hospitalization or consultation
Cardiac, vena cava, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional/Cardiac echo is optional for patients included in consultation
Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation/ Urine analysis is optional for patients included in consultation
Telephone follow-up will be performed 3, 12 and 24
Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Rate of death from all causes
composite endpoint : rate of death from all causes, hospitalisation for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following inclusion (with outcome 2 and 3)
Time frame: 24 months after inclusion
Rate of hospitalisation for acute heart failure
composite endpoint : rate of death from all causes, hospitalisation for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following inclusion (with outcome 1 and 3)
Time frame: 24 months after inclusion
Rate of day-hospital or in-home IV diuretics injection for acute HF
composite endpoint : rate of death from all causes, hospitalisation for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following inclusion (with outcome 1 and 2)
Time frame: 24 months after inclusion
Number of B-lines measured in lung echography
Time frame: At baseline
Rate of death from all causes
composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after inclusion (with outcome 6)
Time frame: 24 months after inclusion
Rate of hospitalisation for acute heart failure
composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after inclusion (with outcome 5)
Time frame: 24 months after inclusion
Rate of death from all causes
Time frame: 24 months after inclusion
Rate of hospitalisation for acute heart failure
composite endpoint: Rate of hospitalisation for acute heart failure or day-hospital/in-home IV diuretics injection for acute HF 24 months after inclusion (with outcome 9)
Time frame: 24 months after day hospitalization
Rate of day-hospital or in-home IV diuretics injection for acute HF
composite endpoint: Rate of hospitalisation for acute heart failure or day-hospital/in-home IV diuretics injection for acute HF 24 months after inclusion (with outcome 8)
Time frame: 24 months after inclusion
Rate of hospitalisation for cardiovascular reason
Time frame: 24 months after inclusion
Rate of death from all causes
composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after inclusion (with outcome 12)
Time frame: 24 months after inclusion
Rate of hospitalisation for acute heart failure
composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after inclusion (with outcome 11)
Time frame: 24 months after inclusion
Rate of cardiovascular death
Time frame: 24 months after inclusion
NYHA (New York Heart Association) class measured
Time frame: 3, 12 and 24 months after inclusion
Natriuretic peptides
BNP or Nt-Pro BNP
Time frame: At baseline
Renal function
Assessed by glomerular filtration rate
Time frame: At baseline
Plasma volume
Calculated from haemoglobin and haematocrit value
Time frame: At baseline
Rate of bilirubin
Time frame: At baseline
Rate of ASAT
Time frame: At baseline
Rate of ALAT
Time frame: At baseline
Rate of V factor
Time frame: At baseline
Blood potassium concentration
Time frame: At baseline
Liver elastography value
Measured with Fibroscan®
Time frame: At inclusion
Quality of life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time frame: At inclusion and 3, 6 and 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2022 (actual). Primary completion is estimated for Dec 2028, 76 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 76 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →